The DOI matches its Crossref record.
Increased Risk of Second Primary Cancers After a Diagnosis of Melanoma
Open accessAbstract
OBJECTIVE: To quantify the risk of subsequent primary cancers among patients with primary cutaneous malignant melanoma. DESIGN: Population-based registry study. SETTING: We evaluated data from 9 cancer registries of the Surveillance, Epidemiology, and End Results program from 1973-2006. PARTICIPANTS: We included 89 515 patients who survived at least 2 months after their initial melanoma diagnosis. RESULTS: Of the patients with melanoma, 10 857 (12.1%) developed 1 or more subsequent primary cancers. The overall risk of a subsequent primary cancer increased by 28% (observed to expected [O:E] ratio = 1.28). One quarter of the cancers were subsequent primary melanomas (O:E = 8.61). Women with head and neck melanoma and patients younger than 30 had markedly increased risks (O:E = 13.22 and 13.40, respectively) of developing a subsequent melanoma. Second melanomas were more likely to be thin than were the first of multiple primary melanomas (thickness at diagnosis <1.00 mm, 77.9% vs 70.3%, respectively; P < .001). Melanoma survivors had increased risk of developing several cancers; the most common cancers with elevated risks were breast, prostate, and non-Hodgkin lymphoma (O:E = 1.10, 1.15, and 1.25, respectively). CONCLUSIONS: Melanoma survivors have an approximately 9-fold increased risk of developing subsequent melanoma compared with the general population. The risk remains elevated more than 20 years after the initial melanoma diagnosis. This increased risk may be owing to behavioral factors, genetic susceptibility, or medical surveillance. Although the percentage of subsequent primary melanomas thicker than 1 mm is lower than for the first of multiple primary melanomas, it is still substantial. Melanoma survivors should remain under surveillance not only for recurrence but also for future primary melanomas and other cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022
Garbe, C., Amaral, T., Peris, K., Hauschild, A., Arenberger, P., Basset-Seguin, N., Bastholt, L., Bataille, V., del Marmol, V., Dréno, B., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.008 · Cited by 329
Larkin, J., Del Vecchio, M., Ascierto, P. A., Krajsova, I., Schachter, J., Neyns, B., Espinosa, E., Garbe, C., Sileni, V. C., Gogas, H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70051-8 · Cited by 278
Dieng, M., Butow, P. N., Costa, D. S. J., Morton, R. L., Menzies, S. W., Mireskandari, S., Tesson, S., Mann, G. J., Cust, A. E., & Kasparian, N. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2278 · Cited by 123
Metadata
- Authors
- Bradford, P. T., Freedman, D. M., Goldstein, A. M., & Tucker, M. A.
- Venue
- Archives of Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2010-03-01
- Volume
- 146
- Issue
- 3
- Pages
- 265-72
- ISSN
- 0003-987X (ISSN-L)
- OpenAlex
- W2127630510
- Cited by
- 247
- References
- 0
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increased Risk of Second Primary Cancers After a Diagnosis of Melanoma. https://app.cochat.ai/papers/10.1001/archdermatol.2010.2
- The paper
- Bradford, P. T., Freedman, D. M., Goldstein, A. M., & Tucker, M. A. (2010). Increased Risk of Second Primary Cancers After a Diagnosis of Melanoma. Archives of Dermatology. https://doi.org/10.1001/archdermatol.2010.2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.